As fears of a tech bubble and stretched valuations turn out to be the speak of the city, buyers are turning to Wall Road titans for steerage, particularly Ken Griffin. Founding hedge fund Citadel in 1990, the agency now boasts over $35 billion price of property beneath administration.As a 19-year-old sophomore at Harvard College, Griffin started buying and selling from his dorm room with a fax machine, pc and telephone. Now, the CEO of Citadel, whose web price stands at $15.5 billion, is called one of many Wall Road greats. Trying on the fund’s efficiency through the COVID disaster, it’s much more clear why Griffin has legendary standing.In contrast to the common hedge fund, which had a adverse return of between 3-4% within the first half of 2020, Citadel’s flagship Wellington fund noticed its returns land between 13-14% for a similar interval.Bearing this in thoughts, we wished to take a better have a look at three shares Citadel snapped up just lately. Utilizing TipRanks’ database, we discovered that every ticker has earned a “Sturdy Purchase” consensus score from the analyst group. To not point out all three of them boast huge upside potential.AVEO Prescribed drugs (AVEO)Hoping to offer higher outcomes for sufferers, AVEO Prescribed drugs advances focused medicines for oncology and different unmet medical wants. Following an essential regulatory milestone, it’s no marvel all eyes are on this healthcare title.Griffin is amongst these singing AVEO’s praises. Rising its holding by a whopping 2,357%, Citadel purchased up 383,720 shares in Q2. With the overall place now touchdown at 400,003 shares, it’s valued at $1,824,013.H.C. Wainwright analyst Swayampakula Ramakanth reminds buyers that on June 1, the FDA accepted the NDA for tivozanib, the corporate’s lead candidate, for evaluate, primarily based on the truth that the TIVO-Three research reported optimistic remaining general survival (OS) information. Within the research, AVEO’s remedy was in comparison with sorafenib, marketed as Nexavar by Bayer, for the remedy of superior renal cell carcinoma (RCC) within the third and fourth-line settings.Trying extra carefully on the information, which was introduced on the ASCO 2020 digital assembly, the ultimate OS evaluation resulted in an general hazard ratio (HR) of 0.97, which favored tivozanib. Ramakanth was “inspired” by the OS outcomes as they “recommend tivozanib at the least has the same general relative threat of deaths in comparison with sorafenib.”“Contemplating that TIVO-Three research met each the first endpoint of development free survival (PFS) and the secondary endpoint of general response price (ORR), with comparable OS to the energetic comparator, we consider tivozanib would possible get a inexperienced gentle for the U.S. approval, which may very well be a significant catalyst within the subsequent 12 months,” Ramakanth opined.Including to the excellent news, the dose escalation for the Section 1b/2 DEDUCTIVE research, evaluating tivozanib together with durvalumab, a monoclonal antibody in opposition to PD-L1 marketed as Imfinzi by AstraZeneca in hepatocellular carcinoma (HCC), has been wrapped up, with it progressing to Section 2. Because the CDC estimates about 33,000 sufferers endure from liver most cancers yearly within the U.S., Ramakanth sees a further alternative.To this finish, Ramakanth charges AVEO a Purchase score together with a $12 value goal. Ought to his thesis play out, a possible twelve-month achieve of 163% may very well be within the playing cards. (To look at Ramakanth’s observe report, click on right here)Different analysts don’t beg to vary. Three Purchase scores and no Holds or Sells have been assigned within the final three months. So, the phrase on the Road is that AVEO is a Sturdy Purchase. The $15 common value goal is extra aggressive than Ramakanth’s and implies 229% upside potential. (See AVEO inventory evaluation on TipRanks)IDEAYA Biosciences (IDYA)Subsequent up we’ve got IDEAYA Biosciences, an oncology-focused precision drugs firm that develops focused therapeutics through the use of molecular diagnostics. Primarily based on the power of its expertise, this title has scored a number of followers.Reflecting a brand new place for Griffin’s Citadel, the fund pulled the set off on 248,005 shares in Q2. As for the worth of this holding, it is available in at $2,881,818. Writing for Northland Capital, analyst Tim Chiang believes shares are “undervalued primarily based on the long run potential of its precision drugs oncology pipeline, which targets particular biomarkers.” Expounding on this, he said, “IDEAYA is making use of its capabilities throughout a number of lessons of precision drugs, together with direct focusing on of oncogenic pathways and artificial lethality – which represents an rising class of precision drugs targets.”A part of what makes IDYA a stand-out, in Chiang’s opinion, is the truth that its preclinical packages use its artificial lethality (SL) platform, which targets tumors with MTAP gene deletion and homologous recombination deficiency (HRD) together with BRCA mutations.“We consider the longer-term upside potential with IDYA shares is critical given the potential utility of SL. The primary clinically validated SL gene pair was PARP-BRCA1/2, and primarily based on the efficacy of PARP inhibitors, the SL method to treating most cancers has achieved substantial industrial validation,” the analyst defined.To again this up, Chiang factors out that a number of PARP inhibitors have already been accredited for the remedy of tumors with BRCA and different DNA injury restore alterations, together with ovarian, breast and pancreatic cancers. These inhibitors embrace AstraZeneca’s olaparib, GlaxoSmithKline’s niraparib, Pfizer’s talazoparib and Clovis’ rucaparib. He added, “We estimate these 4 medicine generated over $1.6 billion in worldwide gross sales in 2019 and are anticipated to succeed in over $6 billion in gross sales by 2024.”It ought to be famous that a number of IND filings are set to return throughout the subsequent 4-12 months, with IDYA’s lead SL candidate, IDE397, which was designed to inhibit MTAP and MAT2A and thus trigger the demise of cancerous tumor cells, getting into the clinic in 2021.It ought to come as no shock, then, that Chiang joined the bulls. To begin off his IDYA protection, he places an Outperform score and $28 value goal on the inventory. This goal implies a attainable twelve-month rise of 141% may very well be on the horizon. (To look at Chiang’s observe report, click on right here)Equally, the remainder of the Road is getting onboard. 5 Purchase scores assigned within the final three months add as much as a Sturdy Purchase analyst consensus. As well as, the $25.20 common value goal places the potential twelve-month achieve at 116%. (See IDYA inventory evaluation on TipRanks)Ocular Therapeutix (OCUL)Utilizing its patented bioresorbable hydrogel-based formulation expertise, Ocular Therapeutix develops cutting-edge therapies for illnesses and circumstances of the attention. The progress of its medical packages has caught Wall Road’s consideration, with some arguing that now could be the time to get in on the motion.Griffin and Citadel didn’t wish to miss out on a possibility. Snapping up 161,032 shares throughout Q2, the hedge fund gave the holding a 272% increase. The entire place is now comprised of 220,269 shares and is valued at $1,718,098.Representing Raymond James, 5-star analyst Dane Leone cites the potential to deal with the unmet wants within the dry eye illness indication as a key part of his bullish thesis. The corporate boasts two property focusing on the situation, OTX-CSI (persistent) and OTX-DED (acute). OTX-CSI incorporates the FDA-approved immunomodulator cyclosporine because the energetic drug within the intracanalicular insert, which is launched for an estimated three months to extend tear manufacturing.On the subject of OTX-DED, Leone argues OCUL was “intelligent in pursuing the event of OTX-DED (a low dose type of DEXTENZA, a corticosteroid intracanalicular insert positioned within the punctum, a pure opening within the eye lid, and into the canaliculus to ship dexamethasone to the ocular floor for as much as 30 days with out preservatives) for the remedy of episodic dry eye, because the prior security information from the DEXTENZA approval enabled administration to file a Section 2-enabling IND by YE20.”Talking to the attainable alternative right here, each merchandise may “present income era for physicians within the remedy of dry eyes utilizing process CPT code 0356T, which may present incentive for fast adoption within the dry eye area that’s presently valued at $5.1 billion,” in Leone’s opinion.As for the medical and regulatory pathway, the Section 2 trial for OTX-DED is about to kick off in 2H21, barely after OTX-CSI, which can see a Section 2 medical trial evaluating two totally different formulations initiated by 4Q20. Primarily based on the quick remedy length of OTX-DED, administration thinks it would nonetheless be dropped at market first.To this finish, Leone stays optimistic concerning the firm’s long-term development narrative. Consequently, he charges OCUL a Sturdy Purchase together with a $15 value goal. This determine implies shares may rise 89% within the 12 months forward. (To look at Leone’s observe report, click on right here) Turning now to the remainder of the Road, different analysts are on the identical web page. With 100% Road assist, or Three Purchase scores to be actual, the consensus is unanimous: OCUL is a Sturdy Purchase. The $13.50 common value goal brings the upside potential to 70%. (See OCUL inventory evaluation on TipRanks)To search out good concepts for shares buying and selling at enticing valuations, go to TipRanks’ Finest Shares to Purchase, a newly launched instrument that unites all of TipRanks’ fairness insights.Disclaimer: The opinions expressed on this article are solely these of the featured analysts. The content material is meant for use for informational functions solely. It is rather essential to do your individual evaluation earlier than making any funding.